stoxline Quote Chart Rank Option Currency Glossary
  
Oyster Point Pharma, Inc. (OYST)
11.17  0 (0%)    12-30 16:00
Open: 11.16
High: 11.2
Volume: 2,088,283
  
Pre. Close: 11.17
Low: 11.12
Market Cap: 0(M)
Technical analysis
2023-01-27 4:46:55 PM
Short term     
Mid term     
Targets 6-month :  13.08 1-year :  15.27
Resists First :  11.19 Second :  13.08
Pivot price 11.15
Supports First :  11.1 Second :  11.03
MAs MA(5) :  11.17 MA(20) :  11.14
MA(100) :  8.89 MA(250) :  8.08
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  81.2 D(3) :  81.2
RSI RSI(14): 65.4
52-week High :  13.77 Low :  3.46
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OYST ] has closed below upper band by 39.6%. Bollinger Bands are 94.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.2 - 11.25 11.25 - 11.3
Low: 11.01 - 11.09 11.09 - 11.15
Close: 11.06 - 11.18 11.18 - 11.27
Company Description

As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Headline News

Tue, 03 Jan 2023
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division - PR Newswire

Thu, 17 Nov 2022
Viatris And Oyster Point – Mylan All Over Again? (NASDAQ:OYST) - Seeking Alpha

Mon, 14 Nov 2022
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Oyster Point Pharma, Inc. - OYST - PR Newswire

Thu, 10 Nov 2022
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Yahoo Finance

Tue, 08 Nov 2022
Oyster Point Pharma to Be Acquired by Viatris - Vision Monday

Mon, 07 Nov 2022
OYST stock on watch after buyout deal with Viatris (NASDAQ:OYST) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 27 (M)
Shares Float 9 (M)
Held by Insiders 1.4 (%)
Held by Institutions 87.3 (%)
Shares Short 289 (K)
Shares Short P.Month 434 (K)
Stock Financials
EPS -4.95
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.83
Profit Margin 0 %
Operating Margin -809.1 %
Return on Assets (ttm) -65.2 %
Return on Equity (ttm) -306.4 %
Qtrly Rev. Growth -68.9 %
Gross Profit (p.s.) 0.85
Sales Per Share 0.72
EBITDA (p.s.) -5.9
Qtrly Earnings Growth 0 %
Operating Cash Flow -166 (M)
Levered Free Cash Flow -97 (M)
Stock Valuations
PE Ratio -2.26
PEG Ratio 0
Price to Book value -13.46
Price to Sales 15.31
Price to Cash Flow -1.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android